Matrix acquires 43 % stake in Explora, Switzerland.

Strategic initiative to gain access to technology platforms and product portfolios such as anti-cancer and corticosteroids

23-Sep-2005

Matrix Laboratories Limited announced that it has acquired 43 per cent stake in Explora Laboratories S.A, a technology platform company based in Mendrisio, Switzerland. Explora Laboratories is engaged in the research and development (R&D) of active pharmaceutical ingredients (APIs) and intermediates through chemical, biochemical and fermentation processes. Explora's expertise in the area of bio-catalysis is very helpful in the development of Corticosteroid and other High Potency APIs such as anti-cancer molecules. It also has expertise in the development of specialized and modified release dosage forms.

Managed by a team of scientists, Explora also possesses know-how in the chemistry of Nucleic Acids (DNA & RNA derivatives) that are mainly used in the development of anti-viral and anti-cancer drugs. Explora has filed two patents to cover its inventions in the area of enzymes immobilization, which is critical for the development of processes involving enzymatic reactions.

Matrix has a large portfolio of products in the therapeutic segments of CNS, cardiovascular, anti-bacterial, anti-viral, anti-retroviral, anti-asthma, anti-histamine, anti-fungal, proton pump inhibitors and pain management. Access to Explora's scientific team would accelerate the entry of Matrix into high potential growth and niche areas such as Corticosteroid and anti-cancer segments. In addition to development of niche generic APIs, Explora's technology platforms would also provide a unique opportunity to Matrix in the area of contract research and manufacturing for the multinational branded pharmaceutical companies.

https://www.chemeurope.com/en/news/49080/matrix-acquires-43-stake-in-explora-switzerland.html